SLC5A2 and heart failure: Statin use has also been investigated in the preventive setting during treatment with anthracyclines, whereas glifozines, or SGLT-2 (sodium/glucose cotransporter-2) inhibitors, approved in 2020 for the treatment of heart failure even without concomitant diabetes, are under investigation for cardioprotection of frail patients during oncological and non-oncological therapies [133,134,135].